WO2014084778A1 - Pyrimidine-2,4-diamine derivatives for treatment of cancer - Google Patents

Pyrimidine-2,4-diamine derivatives for treatment of cancer Download PDF

Info

Publication number
WO2014084778A1
WO2014084778A1 PCT/SE2013/051387 SE2013051387W WO2014084778A1 WO 2014084778 A1 WO2014084778 A1 WO 2014084778A1 SE 2013051387 W SE2013051387 W SE 2013051387W WO 2014084778 A1 WO2014084778 A1 WO 2014084778A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
substituents selected
heteroaryl
represent
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2013/051387
Other languages
English (en)
French (fr)
Inventor
Martin Scobie
Thomas Helleday
Tobias Koolmeister
Sylvain JACQUES
Matthieu Desroses
Marie-Caroline JACQUES-CORDONNIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
Original Assignee
THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014084778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2015006039A priority Critical patent/MX373786B/es
Priority to US14/647,400 priority patent/US9604937B2/en
Priority to SG11201503783VA priority patent/SG11201503783VA/en
Priority to PL13859400T priority patent/PL2925744T3/pl
Priority to KR1020157015196A priority patent/KR102194646B1/ko
Priority to EP13859400.7A priority patent/EP2925744B1/en
Priority to NZ70909413A priority patent/NZ709094A/en
Priority to AU2013353542A priority patent/AU2013353542B2/en
Priority to RU2015125458A priority patent/RU2672916C2/ru
Priority to BR112015011497-0A priority patent/BR112015011497B1/pt
Priority to CA2888338A priority patent/CA2888338C/en
Priority to ES13859400T priority patent/ES2860937T3/es
Priority to JP2015544036A priority patent/JP6322205B2/ja
Priority to DK13859400.7T priority patent/DK2925744T3/da
Priority to MYPI2015001271A priority patent/MY182386A/en
Priority to CN201380061606.XA priority patent/CN105143206B/zh
Priority to HK16103963.9A priority patent/HK1216025B/en
Application filed by THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING filed Critical THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
Publication of WO2014084778A1 publication Critical patent/WO2014084778A1/en
Priority to PH12015501058A priority patent/PH12015501058A1/en
Priority to ZA2015/03470A priority patent/ZA201503470B/en
Priority to IL238942A priority patent/IL238942B/en
Priority to SA515360493A priority patent/SA515360493B1/ar
Anticipated expiration legal-status Critical
Priority to US15/447,818 priority patent/US9944640B2/en
Priority to US15/899,061 priority patent/US10174029B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the invention relates to novel compounds, compositions and methods for treatment of cancer.
  • the invention relates to novel compounds, compositions and methods for the treatment of cancers through inhibition of MTH1.
  • ROS reactive oxygen species
  • ROS mediates tumor-promoting characteristics, such as e.g. unrestrained proliferation, survival signaling, increased migration, angiogenesis.
  • ROS are generated during cell metabolism and are highly reactive with macromolecules such as DNA, proteins and lipids. Exposure of nucleic acids to ROS can create more than 20 oxidatively modified nucleotides, of which 8-oxo- 7,8-dihydroxyguanine (8-oxo-dG) is most abundant.
  • 8-oxo-dG plays a pivotal role in mutagenesis (Sekiguchi and Tsuzuki., Oncogene 21 (58)2002:8895-906) .
  • mammalian cells are armed with a set of repair enzymes to remove the oxidized nucleotides to maintain genome integrity.
  • One of these protective enzymes is MTH1 (MutT homologue 1 , 8-oxo- dGTPase, NUDT1).
  • MTH1 is upregulated in various cancer forms, suggesting that the cancer cell rely on MTH1 function to survive the increased DNA lesion (Human Proteinatlas, Koketsu et al., Hepatogastroenterology, 51(57)2004:638-41). Suppression of MTH1 level and activity by using RNAi technology, leads to reduced cancer cell survival, premature senescence and DNA strand breaks (Rai et al, PNAS, 106(1)2009:169-174), Helleday et al unpublished data).
  • tumour cells reducing the capacity to eliminate oxidised dNTPs by inhibiting MTH1 activity, will reduce cancer cell survival and hence be a promising novel anticancer therapy, either as monotherapy in cancer forms with high oxidative stress levels and/or in combination with radiotherapy and chemotherapy drugs. Shortcomings and complications with current treatment
  • the 4-amino group of the pyrimidine is substituted by either 1 ,3-benzodioxol-5-ylmethyl or by 4-hydroxy- phenethyl.
  • Several scientific publications describe the use of one of the compounds (/V4-(1 ,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-2,4- pyrimidinediamine) as a tool to investigate the wnt-pathway.
  • British patent application GB 681712 describes 2,4-diaminopyrimidines substituted in the 6-position by an aryl group for use in the treatment of cancer, but in only one example the aryl is phenyl and the 4-amino group is substituted by an alkyl. In this compound the phenyl is unsubstituted and the alkyl is methyl. There is no disclosure in this documents of compounds in which the 6-phenyl may be substituted by other groups than chloro or nitro in the para-position, that the 6-phenyl may contain more than one substituent or that the 4-alkylamino- group is larger than methyl or may carry substituents.
  • MTH1 inhibitors have the potential to be very effective against cancer forms with dysfunctional redox status, with minimal general toxic effects. MTH1 inhibition may also be a suitable adjuvant therapy to be used in conjunction with
  • the present invention aims at providing new treatments for cancer that can be achieved by inhibition of MTH1
  • R 1 represents heteroaryl connected to the pyrimidine of formula I via a carbon atom of the heteroaryl ring, which heteroaryl ring ring is optionally substituted by one or more substituents selected from Y 1 , -Ci -6 alkyl optionally substituted by one or more Y 2 and heterocycloalkyi optionally substituted by one or more Y 3 ; or aryl
  • E 1 represents hydrogen, Y 1a , -Ci -6 alkyl optionally substituted by one or more Y 2 or heterocycloalkyi optionally substituted by one or more Y 3 ;
  • E 2 represents hydrogen, Y 1 b , -Ci -6 alkyl optionally substituted by one or more Y 2 or heterocycloalkyi optionally substituted by one or more Y 3 ;
  • E 3 and E 4 each idependently represents hydrogen, Y 1 , -Ci -6 alkyl optionally substituted by one or more Y 2 or heterocycloalkyi optionally substituted by one or more Y 3 ;
  • R 2 represents hydrogen, halogen, -CN, -Ci-i 2 alkyl optionally substituted by one or more Z 1 , or heterocycloalkyi optionally substituted by one or more Z 2 ;
  • R 3 represents -Ci-i 2 alkyl optionally substituted by one or more Z 1 or
  • heterocycloalkyi optionally substituted by one or more Z 2 ;
  • R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 8-membered non-aromatic ring, wherein the link formed by R 2 and R 3 is optionally substituted by one or more substituents selected from Z 3 and -Ci- 9 alkyl optionally substituted by one or more Z 4 ; each Y 1 independently represents halogen, -CN, -C(0)R a , -C(0)N(R b )R c , -C(0)OR d , -N(R e )R f , -N(R 9 )C(0)R h , - ⁇ ) ⁇ (0)0 ⁇ , -N(R k )C(0)N(R')R m , -N0 2 , -N(R n )S(0) 2 R°, -OR p , -OC(0)R q , -OS(0) 2 R r , -S(0) m R s
  • heterocycloalkyi optionally substituted by one or more substituents selected from W 2 , aryl optionally substituted by one or more substituents selected from W 3 or heteroaryl optionally substituted by one or more substituents selected from W 3 ;
  • Y 1a represents halogen, -CN, -C(0)R a , -C(0)N(R b )R c , -C(0)OR d , -N(R e )R f , -N(R 9 )C(0)R h , - ⁇ ( ⁇ )0(0)0 ⁇ , -N(R k )C(0)N(R')R m , -N0 2 , -N(R n )S(0) 2 R°,
  • Y 1 b represents halogen, -CN, -C(0)R a , -C(0)N(R b )R c , -C(0)OR d , -N(R e )R f , -N(R 9 )C(0)R h , - ⁇ )0(0)0 ⁇ , -N(R k )C(0)N(R')R m , -N0 2 , -N(R n )S(0) 2 R°,
  • R py represents hydrogen, -C 2 . 6 alkyl optionally substituted by one or more substituents selected from W 1 , heterocycloalkyl optionally substituted by one or more substituents selected from W 2 , aryl optionally substituted by one or more substituents selected from W 3 , or heteroaryl optionally substituted by one or more substituents selected from W 3 ; each Y 2 independently represents halogen, -CN, -C(0)R b1 , -C(0)N(R c1 )R d1 , -C(0)OR e1 , -N(R f1 )R 91 , -N(R h1 )C(0)R i1 , -N(R j1 )C(0)OR k1 , -N(R l1 )C(0)N(R m1 )R n1 , -N(R 01 )S(0) 2 R p1 , -OR q1 , -
  • each Z 4 independently represents halogen, -CN, -C(0)R b2 , -C(0)N(R c2 )R d2 , -C(0)OR e2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )
  • W 9 represents hydrogen, halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 ,
  • R q3x represents C 2 -6 alkyl optionally substituted by one or more G 3 ; each G 1 and G 2 independently represents halogen, -R a4 , -CN, -C(0)R b4 ,
  • salts include acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin. For the avoidance of doubt, solvates are also included within the scope of the invention.
  • Compounds of the invention may contain double bonds and may thus exist as E (ent ought) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention. Compounds of the invention may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.
  • Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Diastereoisomers may be separated using conventional techniques, e.g.
  • the various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e. a 'chiral pool' method), by reaction of the appropriate starting material with a 'chiral auxiliary' which can subsequently be removed at a suitable stage, by derivatisation (i.e.
  • Ci -q alkyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched- chain, and/or cyclic (so forming a C 3 . q -cycloalkyl group).
  • Such groups may also be part cyclic.
  • Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms, be unsaturated (forming, for example, a C 2 . q alkenyl or a C 2 . q alkynyl group).
  • Ci -q alkylene groups (where q is the upper limit of the range) defined herein may (in a similar manner to the definition of Ci -q alkyl) be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain, and/or cyclic (so forming a C 3 . q -cycloalkylene group). When there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic. Such alkylene groups may also be saturated or, when there is a sufficient number (i.e.
  • halo when used herein, includes fluoro, chloro, bromo and iodo (for example, fluoro and chloro).
  • HeterocydoalkyI groups that may be mentioned include non-aromatic monocyclic and bicyclic heterocycloalkyl groups (which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between three and twelve (e.g. between five and ten and, most preferably, between three and eight, e.g. a 5- or 6-membered heterocycloalkyl group). Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C 2 . q (e.g.
  • C 4 . q heterocycloalkenyl (where q is the upper limit of the range) or a C 7 . q heterocycloalkynyl group.
  • C 2 . q heterocycloalkyl groups that may be mentioned include 7-azabicyclo-[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl,
  • heterocycloalkyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. Further, in the case where the substituent is another cyclic compound, then the cyclic compound may be attached through a single atom on the heterocycloalkyl group, forming a so-called "spiro"-compound.
  • the point of attachment of heterocycloalkyl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heterocycloalkyl groups may also be in the N- or S- oxidised form.
  • a heterocycloalkyl group is preferably a 3- to 8-membered heterocycloalkyl group (e.g. a 5- or 6-membered heterocycloalkyl group).
  • aryl when used herein, includes C 6 -14 (e.g. C 6 -io) aromatic groups. Such groups may be monocyclic or bicyclic and, when bicyclic, be either wholly or partly aromatic.
  • C 6 -io aryl groups that may be mentioned include phenyl, naphthyl, 1 ,2,3,4-tetrahydronaphthyl, indanyl, and the like (e.g. phenyl, naphthyl and the like).
  • the point of attachment of substituents on aryl groups may be via any carbon atom of the ring system.
  • heteroaryl when used herein, includes 5- to 10- membered heteroaromatic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur. Such heteroaryl group may comprise one, or two rings, of which at least one is aromatic. Substituents on
  • heteroaryl/heteroaromatic groups may, where appropriate, be located on any atom in the ring system including a heteroatom.
  • the point of attachment of heteroaryl/heteroaromatic groups may be via any atom in the ring system including (where appropriate) a heteroatom.
  • Bicyclic heteroaryl/heteroaromatic groups may comprise a benzene ring fused to one or more further aromatic or non-aromatic heterocyclic rings, in which instances, the point of attachment of the polycyclic heteroaryl/heteroaromatic group may be via any ring including the benzene ring or the heteroaryl/heteroaromatic or heterocycloalkyl ring.
  • heteroaryl/heteroaromatic groups examples include pyridinyl, pyrrolyl, furanyl, thiophenyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, imidazopyrimidinyl, pyrimidinyl, indolyl, azaindolyl, pyrazinyl, indazolyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl and benzotriazolyl.
  • heteroaryl includes polycyclic (e.g. bicyclic) groups in which one ring is aromatic (and the other may or may not be aromatic).
  • heteroaryl groups that may be mentioned include e.g. benzo[1 ,3]dioxolyl, benzo[1 ,4]dioxinyl, indolinyl, 5H,6H, 7H-pyrrolo[1 ,2-6]pyrimidinyl, 1 ,2,3,4-tetra- hydroquinolinyl and the like.
  • Heteroatoms that may be mentioned include phosphorus, silicon, boron and, preferably, oxygen, nitrogen and sulfur.
  • formula I can thus be represented by
  • n R 3 is -CM 2 alkyl substituted by Z 1 , and Z 1 is represented by
  • the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature). All isotopes of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention.
  • the compounds of the invention also include deuterated compounds, i.e. in which one or more hydrogen atoms are replaced by the hydrogen isotope deuterium.
  • compounds of the invention that are the subject of this invention include those that are stable. That is, compounds of the invention include those that are sufficiently robust to survive isolation from e.g. a reaction mixture to a useful degree of purity.
  • R 2 represents hydrogen or -Ci-i 2 alkyl optionally substituted by one or more Z 1 ;
  • R 3 represents -Ci-i 2 alkyl optionally substituted by one or more Z 1 or
  • heterocycloalkyl optionally substituted by one or more Z 2 .
  • compounds of formula I that may be mentioned include those in which R 2 represents methyl, or preferably, hydrogen and R 3 represents:
  • one Z 1 or -C 2 - 6 alkyl optionally substituted by two, or preferably, one Z 1 or
  • heterocycloalkyl optionally substituted by two, or preferably, one Z 2 ;
  • Particular compounds of formula I include those in which: R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 8-membered non-aromatic ring, wherein the link formed by R 2 and R 3 is optionally substituted by one or more substituents selected from Z 3 or -Ci- 9 alkyl optionally substituted by one or more Z 4 .
  • compounds of formula I include those in which R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 6-membered non-aromatic ring, wherein the non- aromaticring is:
  • Particular compounds of formula I that may be mentioned include those in which: E 1 is Y 1a or -Ci -6 alkyl optionally substituted by one or more Y 2 and at least one of E 2 , E 3 and E 4 represents Y 1 b or -Ci -6 alkyl optionally substituted by one or more Y 2 .
  • Preferred compounds of formula I that may be mentioned include those in which: E 1 is Y 1a or -Ci -3 alkyl optionally substituted by one or more Y 2 and at least one of E 2 and E 4 represents Y 1 b , -Ci -3 alkyl optionally substituted by one or more Y 2 .
  • R 1 represents heteroaryl that may be mentioned are those where R 1 represents benzofuranyl, benzothiophenyl, dihydrobenzofuranyl, indazolyl, indolyl, isoquinolinyl, isoxazolyl, pyridinyl, pyrrolyl and quinolinyl.
  • R 1 represents heteroaryl that may be mentioned are those where R 1 represents benzofuran-3-yl, benzo- thiophen-3-yl, dihydrobenzofuran-7-yl, indol-3-yl, indol-4-yl, indol-5-yl, isoquinolin- 4-yl, isoxazol-4-yl, pyridin-3-yl, pyridin-4-yl, pyrrol-2-yl and quinolin-5-yl.
  • compounds of formula I that may be mentioned include those in which R 1 represents indolyl, e.g. indol-3-yl, indol-4-yl or indol-5-yl, where the indolyl is optionally substituted on the nitrogen with -S(0) 2 Ai x , where Ar* is aryl or heteroaryl, preferably optionally substituted phenyl, e.g. unsubstituted phenyl or phenyl substituted in the 4-position by -F, -CI, -CH 3 or -CF 3 .
  • Particular compounds of formula I that may be mentioned include those in which R 1 is represented by
  • E 2 , E 3 and E 4 represent hydrogen and
  • E 1 represents hydrogen, or more preferably -F, -CI, -CH 3 , -CF 3 , CN or -OCH 3 ;
  • E 1 , E 3 and E 4 represent hydrogen and
  • E 1 , E 2 and E 4 represent hydrogen and
  • -N(H)C(0)CH CH 2 , -N(H)S(0) 2 CH 3 , -OCH(CH 3 ) 2 , -OCH 3 , -OCF 3 , -S(0) 2 CH 3 , or -S(0) 2 (4-morpholinyl).
  • E 3 and E 4 represent hydrogen
  • E 1 represents -F and E 2 represent -F, -CI, -CH 3 or -CF 3 ; or
  • E 1 represents -CI and E 2 represents -F, -CI, -CH 3 or -CF 3 ; or
  • E 1 represents -CH 3 and E 2 represents -F, -CI, -CH 3 , -CF 3 , -CN or
  • E 2 and E 4 represent hydrogen
  • E 1 represents -F and E 3 represents -F or phenyl
  • E 1 represents -CI and E 3 represents -F or -CI; or
  • E 1 represents -CH 3 and E 3 represents -CI or -OCH 2 phenyl; or
  • E 1 represents -OCH 3 and E 3 represents -F; or E 2 and E 3 represent hydrogen; and
  • E 1 represents -F and E 4 represents -CI, -CH 3 or -CN; or
  • E 1 represents -CI and E 4 represent -F, -CI, -CH 3 , -CF 3 or -OCH 3 ; or E 1 represents -CH 3 and E 4 represent -F, -CI, -CH 3 , -CF 3 , -CN,
  • E 1 represents -CF 3 and E 4 represents -F or -CF 3 ;
  • E 1 represents -CN and E 4 represents -CI; or
  • E 1 represents -OCH 3 and E 4 represents -F, -CI, Br, -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CN or -OCH 3 ; or
  • E 1 and E 4 represent hydrogen
  • E 2 represents -F and E 3 represents -F, -CI, -OH or -OCH 3 ; or
  • E 2 represents -CI and E 3 represents -F or -C(0)(4-morpholinyl); or
  • E 2 represents -CH 3 and E 3 represents -F or -OCH 3 ;
  • E 1 represents -OCH 3 and E 3 represents -OH;
  • E 1 represents-CH 2 OCH 3 and E 3 represents (piperidin-4-yl)methoxy or
  • E 1 and E 3 represent hydrogen
  • E 2 and E 4 represent -F;
  • E 2 and E 4 represent -CF 3 ; or E 4 represents hydrogen;
  • E 1 , E 2 and E 3 represent -F;
  • E 1 and E 2 represent -CI and E 3 represents -CI, -OH or -OCH 3 ; or
  • E 1 and E 2 represent -CH 3 and E 3 represents -F or -OCH 3 ; or
  • E 2 and E 3 represent -CI and E 1 represents -CH 3 ; or
  • E 2 represents hydrogen
  • E 1 , E 3 and E 4 represent -F; or
  • E 3 and E 4 represent -CI and E 1 represents -CH 3 ; or
  • E 1 and E 4 represent -CI and E 1 represents -OCH 3 ; or
  • E 1 and E 4 represent -CH 3 and E 3 represents -F, -CH 3 or -OCH 3 ; or
  • E 1 represents -F
  • E 3 represents -CH 3 and E 4 represents -CI
  • E 1 represents -CI
  • E 3 represents -F
  • E 4 represents -CH 3 ;
  • E 1 represents -CI
  • E 3 represents -CH 3 and E 4 represents -F;
  • E 1 and E 4 represent -CH 3 and E 3 represents -F; or
  • E 1 represents -CH 3
  • E 4 represents -CI and E 3 represents -CF 3 or -OCH 3
  • E 1 represents hydrogen
  • E 2 and E 4 represent -CH 3 and E 3 represents -OH; or
  • E 3 represents hydrogen
  • E 1 and E 2 represent -CI and E 4 represents -CH 3 .
  • E 1 , E 3 and E 4 represent hydrogen and
  • E 1 , E 2 and E 4 represent hydrogen and
  • E 3 and E 4 represent hydrogen
  • E 1 represents -F and E 2 represents -F, -CI, or -CF 3 ; or
  • E 1 represents -CI and E 2 represents -CI, -CH 3 or -CF 3 ; or
  • E 2 and E 4 represent hydrogen
  • E 1 and E 3 represent -F;
  • E 1 represents -CI and E 3 represents -F or -CI; or
  • E 1 represents -CH 3 and E 3 represents -CI;
  • E 2 and E 3 represent hydrogen
  • E 1 represents -F and E 4 represents -CI, -CH 3 or -CN; or E 1 represents -CI and E 4 represents -F, -CI, -CH 3 or -CF 3 ; or
  • E 1 represents -CH 3 and E 4 represent, -CI, -CH 3 , -CF 3 , -CN or
  • E 1 represents -CF 3 and E 4 represents -F or -CF 3 ;
  • E 1 represents -CN and E 4 represents -CI; or
  • E 4 represents hydrogen
  • E 1 , E 2 and E 3 represent -F;
  • E 1 and E 2 represent -CH 3 and E 3 represents -F 3 ; or
  • E 2 and E 3 represent -CI and E 1 represents -CH 3 ; or
  • E 2 represents hydrogen
  • E 1 , E 3 and E 4 represent -F; or
  • E 3 and E 4 represent -CI and E 1 represents -CH 3 ; or
  • E 1 and E 4 represent -CH 3 and E 3 represents -F or -CH 3 ; or
  • E 1 represents -F
  • E 3 represents -CH 3 and E 4 represents -CI
  • E 1 represents -CI
  • E 3 represents -F
  • E 4 represents -CH 3 ;
  • E 1 represents -CI
  • E 3 represents -CH 3 and E 4 represents -F;
  • E 1 and E 4 represent -CH 3 and E 3 represents -F; or
  • E 1 represents -CH 3
  • E 3 represents -CF 3
  • E 4 represents -CI
  • E 1 represents hydrogen
  • E 2 and E 4 represent -CH 3 and E 3 represents -OH; or E 3 represents hydrogen;
  • E 1 and E 2 represent -CI and E 4 represents -CH 3 .
  • Preferred compounds of formula I include those in which: (a) Z 1 is not present or is selected from -F, -CN, -C(0)R b2 , -C(0)N(R c2 )R d2 , -C(0)OR e2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SCO ⁇ N ⁇ R 2 , heterocycloalkyl optionally by one or more substituents selected from W 5 , aryl represented by , or heteroaryl having 1 to 3 nitrogen atoms, one oxygen atom and/or one sulfur atom and optionally substitute
  • Z 3 is not present or is selected from -F, -R a2 , -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , - S(0) m R t2 , -SCO ⁇ NKR ⁇ R” 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 ; and/or
  • Z 4 is not present or is selected from -F, -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SCO ⁇ NKR ⁇ R 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 .
  • Particularly preferred compounds of formula I that may be mentioned include those in which Z 1 represents -F, -CN, -C(0)
  • Preferred compounds of formula I where Z 1 represents heterocycloalkyl that may be mentioned are those where Z 1 represents dihydropyridinyl, imidazolinyl, morpholinyl, oxanyl, piperazinyl, piperidinyl, pyrrolidinyl and quinuclidinyl, wherein the heterocycloalkyi is optionally substituted by one or more substituents selected from W 5 .
  • each W 7 , W 10 and W 11 independently represents hydrogen, halogen, -R a3 or -CN;
  • one of W 8 and W 9 represents hydrogen, halogen, -R a3 or -CN and the other represents halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 , -N(R j3 )C(0)OR k3 , -N(R l3 )C(0)N(R m3 )R n3 , -N(R o3 )S(0) 2 R p3 , -OR q3x , -OC(0)R r3 , -OS(0) 2 R s3 , -S(0) m R t3 , -S O ⁇ N R ⁇ R 3 , heterocycloalkyi optionally substituted by one or more substituents selected from G 1
  • each W 7 , W 10 and W 11 independently represents -F, -CI, -CH 3 , -CF 3 , or more preferably, hydrogen;
  • W 8 and W 9 represents -F, -CI, -CH 3 , -CF 3 , or more preferably, hydrogen, and the other (preferably W 9 ) represents halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 ,
  • W 8 , W 9 , W 10 and W 11 represents hydrogen and W 7 represents -CI or -S(0) 2 CH 3 ;
  • W 7 , W 9 , W 10 and W 11 represents hydrogen and W 8 represents -F, -Br, -CN, -N(H)C(0)CH 3 , -OCH3 or -S(0) 2 CH 3 ; or
  • W 8 and W 9 represents -F or -CI
  • W 8 represents -F and W 9 represents -CH 3 .
  • W 7 , W 8 , W 10 and W 11 are hydrogen and W 9 represents halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 , -N(R j3 )C(0)OR k3 , -N(R l3 )C(0)N(R m3 )R n3 ,
  • W 7 , W 8 , W 10 and W 11 are hydrogen and W 9 represents -F, -CI, -CH 3 , cyclopropyl, -CF 3 , -CN, -NH 2 , -N(CH 3 ) 2 , -N(H)C(0)CH 3 , -N(H)C(0)OC(CH 3 ) 3 , -S0 2 CH 3 , -S0 2 NH 2 , -S(0) 2 N(CH 3 ) 2 , -S(0) 2 -4-morpholinyl, 4-methylpiperazin-1-yl, 4-methylpiperidin-1-ylmethyl and 1 ,2,3-thiadiazol-4-yl.
  • Preferred compounds of formula I where Z 1 represents heteroaryl are those where Z 1 represents benzimidazolyl, benzodioxinyl, benzoxazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, isoquinolinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolopyridinyl, quinolinyl, thiazolyl, thiophenyl and triazolyl, wherein the heteroaryl is optionally substituted by one or more substituents selected from W 6 .
  • Z 1 represents heteroaryl that may be mentioned are those where Z 1 represents benzimidazol-2-yl, 1 ,4-benzo- dioxin-2-yl, benzoxazol-2-yl, furan-2-yl, imidazol-1-yl, imidazol-4-yl, imidazo- [1 ,2-a]pyridin-2-yl, indol-3-yl, indol-5-yl, isoquinolin-4-yl, 1 ,3,4-oxadiazol-2-yl, 1 ,2-oxazol-4-yl, pyrazin-3-yl, pyrazol-1-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5/-/,6/-/,7/-/-pyrrolo[3,4-£>]pyridin-5-yl, thiazol-5-y
  • More particularly preferred compounds of formula I that may be mentioned are those where W 6 represents -F, -CI, -Br, -CH 3 , cyclopropyl, -CF 3 , -CN, -NH 2 , -N(CH 3 ) 2 , -SO2CH3, -SO2NH2 and -SO) 2 N(CH 3 ) 2 .
  • R 1 represents:
  • indanyl, naphthyl, tetrahydronaphthyl or heteroaryl the latter connected to the pyrimidine of formula I via a carbon atom of the heteroaryl ring, which indanyl, naphthyl, tetrahydronaphthyl and heteroaryl rings are optionally substituted by one or more substituents selected from Y 1 , -Ci -6 alkyl optionally substituted by one or more Y 2 and heterocycloalkyl optionally substituted by one or more Y 3 ; or nted by
  • E 1 , E 2 , E 3 and E 4 represents hydrogen, Y 1 , -Ci -6 alkyl optionally substituted by one or more Y 2 or heterocycloalkyl optionally substituted by one or more Y 3 , but where at least one of E 1 , E 2 , E 3 and E 4 is other than hydrogen;
  • R 2 represents hydrogen, halogen or -Ci-i 2 alkyl optionally substituted by one or more Z 1 ;
  • R 3 represents -Ci-i 2 alkyl substituted by one or more Z 1 or heterocycloalkyl optionally substituted by one or more Z 2 ; or R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 8-membered non-aromatic ring, wherein the link formed by R 2 and R 3 is optionally substituted by one or more substituents selected from Z 3 or -Ci- 9 alkyl optionally substituted by one or more Z 4 ; each Y 1 independently represents halogen, -CN, -C(0)R a , -C(0)N(R b )R c , - C(0)OR d ,
  • each Z 2 and Z 3 independently represents halogen, -R a2 , -CN, -C(0)R b2 ,
  • each Z 4 independently represents halogen, -CN, -C(0)R b2 , -C(0)N(R c2 )R d2 , -C(0)OR e2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )
  • W 7 and W 11 represents hydrogen; each W 8 and W 10 independently represents hydrogen, halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 , -N(R j3 )C(0)OR k3 , -N(R l3 )C(0)N(R m3 )R n3 , -N(R o3 )S(0) 2 R p3 , -OR q3 , -OC(0)R r3 , -OS(0) 2 R s3 , -S(0) m R t3 , -SCO ⁇ N R ⁇ R" 3 , heterocycloalkyl optionally substituted by one or more substituents selected from G 1 , aryl optionally substituted by one or
  • W 9 represents halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 ,
  • R q3x represents C 2 -6 alkyl optionally substituted by one or more G 3 ; each G 1 and G 2 independently represents halogen, -R a4 , -CN, -C(0)R b4 ,
  • salts include acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin. For the avoidance of doubt, solvates are also included within the scope of the invention.
  • Compounds of the invention may contain double bonds and may thus exist as E (ent ought) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention. Compounds of the invention may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.
  • Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Diastereoisomers may be separated using conventional techniques, e.g.
  • the various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e. a 'chiral pool' method), by reaction of the appropriate starting material with a 'chiral auxiliary' which can subsequently be removed at a suitable stage, by derivatisation (i.e.
  • Ci -q alkyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched- chain, and/or cyclic (so forming a C 3 . q -cycloalkyl group).
  • Such groups may also be part cyclic.
  • Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms, be unsaturated (forming, for example, a C 2 . q alkenyl or a C 2 . q alkynyl group).
  • Ci -q alkylene groups (where q is the upper limit of the range) defined herein may (in a similar manner to the definition of Ci -q alkyl) be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain, and/or cyclic (so forming a C 3 . q -cycloalkylene group). When there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic. Such alkylene groups may also be saturated or, when there is a sufficient number (i.e.
  • alkylene groups that may be mentioned include those that are straight-chained and saturated.
  • halo when used herein, includes fluoro, chloro, bromo and iodo (for example, fluoro and chloro).
  • HeterocydoalkyI groups that may be mentioned include non-aromatic monocyclic and bicyclic heterocycloalkyl groups (which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between three and twelve (e.g. between five and ten and, most preferably, between three and eight, e.g. a 5- or 6-membered heterocycloalkyl group). Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C 2 . q (e.g.
  • C 4 . q heterocycloalkenyl (where q is the upper limit of the range) or a C 7 . q heterocycloalkynyl group.
  • C 2 . q heterocycloalkyl groups that may be mentioned include 7-azabicyclo-[2.2.1 ]heptanyl , 6-azabicyclo[3.1.1 ]heptanyl,
  • heterocycloalkyi groups may, where appropriate, be located on any atom in the ring system including a heteroatom. Further, in the case where the substituent is another cyclic compound, then the cyclic compound may be attached through a single atom on the heterocycloalkyi group, forming a so-called "spiro"-compound.
  • the point of attachment of heterocycloalkyi groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heterocycloalkyi groups may also be in the N- or S- oxidised form.
  • a heterocycloalkyi group is preferably a 3- to 8-membered heterocycloalkyi group (e.g. a 5- or 6- membered heterocycloalkyi group).
  • aryl when used herein, includes C 6 -14 (e.g. C 6 -io) aromatic groups. Such groups may be monocyclic or bicyclic and, when bicyclic, be either wholly or partly aromatic.
  • C 6 -io aryl groups that may be mentioned include phenyl, naphthyl, 1 ,2,3,4-tetrahydronaphthyl, indanyl, and the like (e.g. phenyl, naphthyl and the like).
  • the point of attachment of substituents on aryl groups may be via any carbon atom of the ring system.
  • heteroaryl when used herein, includes 5- to 10- membered heteroaromatic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur. Such heteroaryl group may comprise one, or two rings, of which at least one is aromatic. Substituents on
  • heteroaryl/heteroaromatic groups may, where appropriate, be located on any atom in the ring system including a heteroatom.
  • the point of attachment of heteroaryl/heteroaromatic groups may be via any atom in the ring system including (where appropriate) a heteroatom.
  • Bicyclic heteroaryl/heteroaromatic groups may comprise a benzene ring fused to one or more further aromatic or non-aromatic heterocyclic rings, in which instances, the point of attachment of the polycyclic heteroaryl/heteroaromatic group may be via any ring including the benzene ring or the heteroaryl/heteroaromatic or heterocycloalkyl ring.
  • heteroaryl/heteroaromatic groups examples include pyridinyl, pyrrolyl, furanyl, thiophenyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, imidazopyrimidinyl, pyrimidinyl, indolyl, azaindolyl, pyrazinyl, indazolyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl and benzotriazolyl.
  • heteroaryl includes polycyclic (e.g. bicyclic) groups in which one ring is aromatic (and the other may or may not be aromatic).
  • heteroaryl groups that may be mentioned include e.g. benzo[1 ,3]dioxolyl, benzo[1 ,4]dioxinyl, indolinyl, 5H,6H, 7H-pyrrolo[1 ,2-6]pyrimidinyl, 1 ,2,3,4-tetra- hydroquinolinyl and the like.
  • Heteroatoms that may be mentioned include phosphorus, silicon, boron and, preferably, oxygen, nitrogen and sulfur.
  • formula I can thus be represented by
  • R 3 is -CM 2 alkyl substituted by Z 1
  • Z 1 is represented by
  • the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature). All isotopes of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention.
  • the compounds of the invention also include deuterated compounds, i.e. in which one or more hydrogen atoms are replaced by the hydrogen isotope deuterium.
  • compounds of the invention that are the subject of this invention include those that are stable. That is, compounds of the invention include those that are sufficiently robust to survive isolation from e.g. a reaction mixture to a useful degree of purity.
  • R 2 represents hydrogen or -Ci.i 2 alkyl optionally substituted by one or more Z 1 ;
  • R 3 represents -Ci-i 2 alkyl substituted by one or more Z 1 or heterocycloalkyl optionally substituted by one or more Z 2 .
  • compounds of formula I that may be mentioned include those in which R 2 represents methyl, or preferably, hydrogen and R 3 represents:
  • Particular compounds of formula I include those in which: R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 8-membered non-aromatic ring, wherein the link formed by R 2 and R 3 is optionally substituted by one or more substituents selected from Z 3 or -Ci- 9 alkyl optionally substituted by one or more Z 4 .
  • compounds of formula I include those in which R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 6-membered non-aromatic ring, wherein the non-aromatic ring is:
  • R 1 represents heteroaryl that may be mentioned are those where R 1 represents benzofuranyl, benzothiophenyl, dihydrobenzofuranyl, indazolyl, indolyl, isoquinolinyl, pyridinyl, pyrrolyl and quinolinyl.
  • compounds of formula I that may be mentioned include those in which R 1 represents indolyl, e.g. indol-3-yl, indol-4-yl or indol-5-yl, where the indolyl is optionally substituted on the nitrogen with -S(0) 2 Ai x , where Ar* is aryl or heteroaryl, preferably optionally substituted phenyl, e.g. unsubstituted phenyl or phenyl substituted in the 4-position by -F, -CI, -CH 3 or -CF 3 .
  • Preferred compounds of formula I that may be mentioned include those in which R 1 is represented by
  • E 2 , E 3 and E 4 represent hydrogen and
  • E 1 represents -F, -CI, -CH 3 , -CF 3 , CN or -OCH 3 ;
  • R 1 is represented by where:
  • E 3 and E 4 represent hydrogen
  • E 1 represents -F and E 2 represent -F, -CI, -CH 3 or -CF 3 ; or
  • E 1 represents -CI and E 2 represents -F, -CI, -CH 3 or -CF 3 ; or
  • E 1 represents -CH 3 and E 2 represents -F, -CI, -CH 3 , -CF 3 or -CN; or
  • E 2 and E 4 represent hydrogen
  • E 1 represents -CI and E 3 represents -F or -CI; or
  • E 1 represents -CH 3 and E 3 represents -CI;
  • E 1 represents -OCH 3 and E 3 represents -F;
  • E 2 and E 3 represent hydrogen
  • E 1 represents -F and E 4 represents -CI, -CH 3 or -CN; or
  • E 1 represents -CI and E 4 represent -F, -CI, -CH 3 , -CF 3 or -OCH 3 ; or
  • E 1 represents -CH 3 and E 4 represent -F, -CI, -CH 3 , -CF 3 or -CN; or
  • E 1 represents -CF 3 and E 4 represents -F or -CF 3 ;
  • E 1 represents -CN and E 4 represents -CI; or
  • E 1 represents -OCH 3 and E 4 represents -F, -CI, Br, -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CN or -OCH 3 ; or E 1 and E 4 represent hydrogen; and
  • E 2 represents -F and E 3 represents -F, -CI, -OH or -OCH 3 ; or
  • E 2 represents -CI and E 3 represents -F;
  • E 2 represents -CH 3 and E 3 represents -F or -OCH 3 ;
  • E 1 represents -OCH 3 and E 3 represents -OH;
  • E 1 and E 3 represent hydrogen
  • E 2 and E 4 represent -F;
  • E 2 and E 4 represent -CF 3 ; or E 4 represents hydrogen;
  • E 1 , E 2 and E 3 represent -F;
  • E 1 and E 2 represent -CI and E 3 represents -CI, -OH or -OCH 3 ; or
  • E 1 and E 2 represent -CH 3 and E 3 represents -F or -OCH 3 ; or
  • E 2 and E 3 represent -CI and E 1 represents -CH 3 ; or
  • E 2 represents hydrogen
  • E 1 , E 3 and E 4 represent -F; or
  • E 3 and E 4 represent -CI and E 1 represents -CH 3 ; or
  • E 1 and E 4 represent -CI and E 1 represents -OCH 3 ; or
  • E 1 and E 4 represent -CH 3 and E 3 represents -F, -CH 3 or -OCH 3 ; or
  • E 1 represents -F
  • E 3 represents -CH 3 and E 4 represents -CI
  • E 1 represents -CI
  • E 3 represents -F
  • E 4 represents -CH 3 ;
  • E 1 represents -CI
  • E 3 represents -CH 3 and E 4 represents -F;
  • E 1 and E 4 represent -CH 3 and E 3 represents -F; or
  • E 1 represents -CH 3
  • E 4 represents -CI
  • E 3 represents -CF 3 or -OCH 3 ;or
  • E 1 represents hydrogen
  • E 2 and E 4 represent -CH 3 and E 3 represents -OH; or
  • E 3 represents hydrogen
  • E 1 and E 2 represent -CI and E 4 represents -CH 3 .
  • Preferred compounds of formula I that may be mentioned include those in which: (a) Z 1 represents halogen, -CN, -C(0)R b2 , -C(0)N(R c2 )R d2 , -C(0)OR e2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SCO ⁇ NKR ⁇ R" 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl represented by
  • Z 2 is not present or is selected from -F, -R a2 , -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SiO ⁇ N R ⁇ R 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl optionally substituted by one or more substituents selected from W 6 ;
  • Z 3 is not present or is selected from -F, -R a2 , -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SiO ⁇ N R ⁇ R 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 ; and/or
  • Z 4 is not present or is selected from -F, -C(0)N(R c2 )R d2 , -N(R f2 )R 92 ,
  • More particularly preferred compounds of formula I include those in which Z 1 represents -F, -CN, -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SCO ⁇ NKR ⁇ R" 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl represented by
  • heteroaryl having 1 to 3 nitrogen atoms, one oxygen atom and/or one sulfur atom and optionally substituted by one or more substituents selected from W 6 .
  • Z 1 represents -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SiOJaNiR ⁇ R ⁇ or aryl represented by
  • R c2 , R f2 , R h2 , R' 2 , R m2 , R 02 , and R u2 represents hydrogen
  • Rd2 R9 2 Ri2 R n 2 rP 2 R q 2 R t2 and R v2 represents ary
  • Preferred compounds of formula I that may be mentioned are those where where where Z 1 represents -OR q2 and R q2 represents aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 .
  • More preferred compounds of formula I that may be mentioned are those where Z 1 represents -N(R f2 )R 92 , R f2 represents hydrogen and R 92 represents aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 .
  • Preferred compounds of formula I where Z 1 represents heterocycloalkyl that may be mentioned are those where Z 1 represents dihydropyridinyl, imidazolinyl, oxanyl, piperazinyl, piperidinyl, pyrrolidinyl and quinuclidinyl, wherein the heterocycloalkyl is optionally substituted by one or more substituents selected from W 5 .
  • Preferred compounds of formula I where Z 1 represents that may be mentioned are those where:
  • each W 8 and W 10 are independently selected from -F, -CI, -CH 3 ,
  • W 9 is selected from -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 ,
  • each W 9 and W 10 are independently selected from -F, -CI, -CH 3 ,
  • W 8 is selected from -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 ,
  • W 8 and W 10 represents hydrogen and W 9 represents -F, -CI, -CH 3 , cyclopropyl, -CF 3 , -CN, -NH 2 , -N(CH 3 ) 2 , -N(H)C(0)CH 3 , -N(H)C(0)OC(CH 3 ) 3 , -S0 2 CH 3 , -S0 2 NH 2 , -S(0) 2 N(CH 3 ) 2 , -S(0) 2 -4-morpholinyl, 4-methylpiperazin-1-yl, 4-methylpiperidin-1-ylmethyl and 1 ,2,3-thiadiazol-4-yl; or
  • W 9 and W 10 represents hydrogen and W 8 represents -F, -CI, -CN, -CH 3 , -NMe 2 , -S(0) 2 NH 2 or -S(0) 2 NMe 2 .
  • Preferred compounds of formula I where Z 1 represents heteroaryl that may be mentioned are those where Z 1 represents benzimidazolyl, benzodioxinyl, benzoxazolyl, imidazolyl, imidazopyridinyl, indolyl, isoquinolinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolopyridinyl, quinolinyl, thiazolyl, thiophenyl and triazolyl, wherein the heteroaryl is optionally substituted by one or more substituents selected from W 6 .
  • Z 1 represents heteroaryl that may be mentioned are those where Z 1 represents benzimidazol-2-yl, 1 ,4-benzo- dioxin-2-yl, benzoxazol-2-yl, imidazol-1-yl, imidazol-4-yl, imidazo[1 ,2-a]pyridin-2- yl, indol-3-yl, indol-5-yl, isoquinolin-4-yl, 1 ,3,4-oxadiazol-2-yl, 1 ,2-oxazol-4-yl, pyrazin-3-yl, pyrazol-1-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5/-/,6/-/,7/-/-pyrrolo[3,4- 5]pyridin-5-yl, thiazol-5-yl, thiophen-2-
  • More particularly preferred compounds of formula I that may be mentioned are those where W 6 represents -F, -CI, -Br, -CH 3 , cyclopropyl, -CF 3 , -CN, -NH 2 , -N(CH 3 ) 2 , -SO2CH3, -SO2NH2 and -SO) 2 N(CH 3 ) 2 .
  • R 1 represents heteroaryl connected to the pyrimidine of formula I via a carbon atom of the heteroaryl ring, which heteroaryl ring is substituted by one or more substituents selected from Y 1 , -Ci -6 alkyl optionally substituted by one or more Y 2 and heterocycloalkyl optionally substituted by one or more Y 3 ; or aryl represented by
  • E 1 represents Y 1a or -Ci -6 alkyl optionally substituted by one or more Y 2 ; and at least one of E 2 , E 3 and E 4 represents Y 1 b or -Ci -6 alkyl optionally substituted by one or more Y 2 ;
  • R 2 represents hydrogen, halogen, -CN, -Ci-i 2 alkyl optionally substituted by one or more Z 1 , or heterocycloalkyl optionally substituted by one or more Z 2 ;
  • R 3 represents -Ci-i 2 alkyl optionally substituted by one or more Z 1 or
  • heterocycloalkyl optionally substituted by one or more Z 2 ;
  • R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 8-membered non-aromatic ring, wherein the link formed by R 2 and R 3 is optionally substituted by one or more substituents selected from Z 3 and -Ci- 9 alkyl optionally substituted by one or more Z 4 ; each Y 1 independently represents halogen, -CN, -C(0)R a , -C(0)N(R b )R c , -C(0)OR d , -N(R e )R f , -N(R 9 )C(0)R h , - ⁇ ) ⁇ (0)0 ⁇ , -N(R k )C(0)N(R')R m , -N0 2 , -N(R n )S(0) 2 R°, -OR p , -OC(0)R q , -OS(0) 2 R r , -S(0) m R s
  • heterocycloalkyl optionally substituted by one or more substituents selected from W 2 , aryl optionally substituted by one or more substituents selected from W 3 or heteroaryl optionally substituted by one or more substituents selected from W 3 ;
  • Y 1a represents halogen, -CN, -C(0)R a , -C(0)N(R b )R c , -C(0)OR d , -N(R e )R f , -N(R 9 )C(0)R h , -NiR'jCiOJOR', -N(R k )C(0)N(R')R m , -N0 2 , -N(R n )S(0) 2 R°,
  • Y 1 b represents halogen, -CN, -C(0)R a , -C(0)N(R b )R c , -C(0)OR d , -N(R e )R f , -N(R 9 )C(0)R h , -NiR'jCiOJOR', -N(R k )C(0)N(R')R m , -N0 2 , -N(R n )S(0) 2 R°,
  • each R a , R b , R c , R d , R e , R 9 , R h , , R k , R 1 , R m , R n , R p , R q , R s , R l and R u independently represents hydrogen, -Ci_ 6 alkyl optionally substituted by one or more substituents selected from W 1 , heterocycloalkyl optionally substituted by one or more substituents selected from W 2 , aryl optionally substituted by one or
  • each Z 4 independently represents halogen, -CN, -C(0)R b2 , -C(0)N(R c2 )R d2 , -C(0)OR e2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )
  • salts include acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin. For the avoidance of doubt, solvates are also included within the scope of the invention.
  • Compounds of the invention may contain double bonds and may thus exist as E (entadel) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.
  • Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Diastereoisomers may be separated using conventional techniques, e.g.
  • the various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e. a 'chiral pool' method), by reaction of the appropriate starting material with a 'chiral auxiliary' which can subsequently be removed at a suitable stage, by derivatisation (i.e.
  • a resolution for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person. All stereoisomers and mixtures thereof are included within the scope of the invention.
  • Ci -q alkyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched- chain, and/or cyclic (so forming a C 3 . q -cycloalkyl group). When there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic. Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms, be unsaturated (forming, for example, a C 2 . q alkenyl or a C 2 . q alkynyl group).
  • Ci -q alkylene groups (where q is the upper limit of the range) defined herein may (in a similar manner to the definition of Ci -q alkyl) be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain, and/or cyclic (so forming a C 3 . q -cycloalkylene group). When there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic. Such alkylene groups may also be saturated or, when there is a sufficient number (i.e.
  • halo when used herein, includes fluoro, chloro, bromo and iodo (for example, fluoro and chloro).
  • HeterocydoalkyI groups that may be mentioned include non-aromatic monocyclic and bicyclic heterocycloalkyl groups (which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between three and twelve (e.g. between five and ten and, most preferably, between three and eight, e.g. a 5- or 6-membered heterocycloalkyl group). Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C 2 . q (e.g.
  • C 4 . q heterocycloalkenyl (where q is the upper limit of the range) or a C 7 . q heterocycloalkynyl group.
  • C 2 . q heterocycloalkyl groups that may be mentioned include 7-azabicyclo-[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl,
  • heterocycloalkyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. Further, in the case where the substituent is another cyclic compound, then the cyclic compound may be attached through a single atom on the heterocycloalkyl group, forming a so-called "spiro"-compound.
  • the point of attachment of heterocycloalkyl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system.
  • Heterocycloalkyl groups may also be in the N- or S- oxidised form.
  • a heterocycloalkyl group is preferably a 3- to 8-membered heterocycloalkyl group (e.g. a 5- or 6-membered heterocycloalkyl group).
  • aryl when used herein, includes C 6 -14 (e.g. C 6 -io) aromatic groups. Such groups may be monocyclic or bicyclic and, when bicyclic, be either wholly or partly aromatic.
  • C 6 -io aryl groups that may be mentioned include phenyl, naphthyl, 1 ,2,3,4-tetrahydronaphthyl, indanyl, and the like (e.g. phenyl, naphthyl and the like).
  • the point of attachment of substituents on aryl groups may be via any carbon atom of the ring system.
  • heteroaryl when used herein, includes 5- to 10- membered heteroaromatic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur. Such heteroaryl group may comprise one, or two rings, of which at least one is aromatic. Substituents on
  • heteroaryl/heteroaromatic groups may, where appropriate, be located on any atom in the ring system including a heteroatom.
  • the point of attachment of heteroaryl/heteroaromatic groups may be via any atom in the ring system including (where appropriate) a heteroatom.
  • Bicyclic heteroaryl/heteroaromatic groups may comprise a benzene ring fused to one or more further aromatic or non-aromatic heterocyclic rings, in which instances, the point of attachment of the polycyclic heteroaryl/heteroaromatic group may be via any ring including the benzene ring or the heteroaryl/heteroaromatic or heterocycloalkyl ring.
  • heteroaryl/heteroaromatic groups examples include pyridinyl, pyrrolyl, furanyl, thiophenyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, imidazopyrimidinyl, pyrimidinyl, indolyl, azaindolyl, pyrazinyl, indazolyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl and benzotriazolyl.
  • heteroaryl includes polycyclic (e.g. bicyclic) groups in which one ring is aromatic (and the other may or may not be aromatic).
  • heteroaryl groups that may be mentioned include e.g. benzo[1 ,3]dioxolyl, benzo[1 ,4]dioxinyl, indolinyl, 5H,6H, 7H-pyrrolo[1 ,2-6]pyrimidinyl, 1 ,2,3,4-tetra- hydroquinolinyl and the like.
  • Heteroatoms that may be mentioned include phosphorus, silicon, boron and, preferably, oxygen, nitrogen and sulfur.
  • formula I can thus be represented by
  • n R 3 is -CM 2 alkyl substituted by Z 1 , and Z 1 is represented by
  • the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature). All isotopes of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention.
  • the compounds of the invention also include deuterated compounds, i.e. in which one or more hydrogen atoms are replaced by the hydrogen isotope deuterium.
  • compounds of the invention that are the subject of this invention include those that are stable. That is, compounds of the invention include those that are sufficiently robust to survive isolation from e.g. a reaction mixture to a useful degree of purity.
  • R 2 represents hydrogen or -Ci-i 2 alkyl optionally substituted by one or more Z 1 ;
  • R 3 represents -Ci-i 2 alkyl optionally substituted by one or more Z 1 or
  • heterocycloalkyl optionally substituted by one or more Z 2 .
  • compounds of formula I that may be mentioned include those in which R 2 represents methyl, or preferably, hydrogen and R 3 represents:
  • Particular compounds of formula I include those in which: R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 8-membered (e.g. a 5- to 6 membered) non-aromatic ring, wherein the link formed by R 2 and R 3 is optionally substituted by one or more substituents selected from Z 3 or -Ci -9 alkyl optionally substituted by one or more Z 4 .
  • compounds of formula I that may be mentioned include those in which R 2 and R 3 are linked together to form, along with the atoms to which they are attached, a 5- to 6-membered non-aromatic ring, wherein the non- aromaticring is:
  • Preferred compounds of formula I include those in which E 1 represents Y 1a or -Ci -6 alkyl optionally substituted by one or more Y 2 ; and at least one of E 2 , E 3 and E 4 (preferably at least one of E 2 and E 4 ) represents Y 1 b or -Ci -6 alkyl optionally substituted by one or more Y 2 .
  • Particular compounds of formula I that may be mentioned include those in which R 1 represents heteroaryl.
  • Preferred compounds of formula I where R 1 represents heteroaryl that may be mentioned are those where R 1 represents benzofuranyl, benzothiophenyl, dihydrobenzofuranyl, indazolyl, indolyl, isoquinolinyl, isoxazolyl, pyridinyl, pyrrolyl and quinolinyl.
  • R 1 represents heteroaryl
  • R 1 represents benzofuran-3-yl, benzo- thiophen-3-yl, dihydrobenzofuran-7-yl, indol-3-yl, indol-4-yl, indol-5-yl, isoquinolin- 4-yl, isoxazol-4-yl, pyridin-3-yl, pyridin-4-yl, pyrrol-2-yl and quinolin-5-yl.
  • compounds of formula I that may be mentioned include those in which R 1 represents indolyl, e.g.
  • indol-3-yl, indol-4-yl or indol-5-yl where the indolyl is optionally substituted on the nitrogen with -S(0) 2 Ai x
  • Ar* is aryl or heteroaryl, preferably optionally substituted phenyl, e.g. unsubstituted phenyl or phenyl substituted in the 4-position by -F, -CI, -CH 3 or -CF 3 .
  • E 3 and E 4 represent hydrogen
  • E 1 represents -F and E 2 represent -F, -CI, -CH 3 or -CF 3 ; or E 1 represents -CI and E 2 represents -F, -CI, -CH 3 or -CF 3 ; or E 1 represents -CH 3 and E 2 represents -F, -CI, -CH 3 , -CF 3 , -CN or
  • E 1 represents -F and E 3 represents -F or phenyl
  • E 1 represents -CI and E 3 represents -F or -CI; or
  • E 1 represents -CH 3 and E 3 represents -CI or -OCH 2 phenyl; or
  • E 1 represents -OCH 3 and E 3 represents -F;
  • E 2 and E 3 represent hydrogen
  • E 1 represents -F and E 4 represents -CI, -CH 3 or -CN; or
  • E 1 represents -CI and E 4 represent -F, -CI, -CH 3 , -CF 3 or -OCH 3 ; or
  • E 1 represents -CH 3 and E 4 represent -F, -CI, -CH 3 , -CF 3 , -CN,
  • E 1 represents -CF 3 and E 4 represents -F or -CF 3 ;
  • E 1 represents -CN and E 4 represents -CI; or
  • E 1 represents -OCH 3 and E 4 represents -F, -CI, Br, -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CN or -OCH 3 ; or
  • E 1 and E 4 represent hydrogen
  • E 2 represents -F and E 3 represents -F, -CI, -OH or -OCH 3 ; or
  • E 2 represents -CI and E 3 represents -F or -C(0)(4-morpholinyl); or
  • E 2 represents -CH 3 and E 3 represents -F or -OCH 3 ;
  • E 1 represents -OCH 3 and E 3 represents -OH;
  • E 1 represents-CH 2 OCH 3 and E 3 represents (piperidin-4-yl)methoxy or
  • E 1 and E 3 represent hydrogen
  • E 2 and E 4 represent -F;
  • E 2 and E 4 represent -CF 3 ;
  • E 4 represents hydrogen
  • E 1 , E 2 and E 3 represent -F;
  • E 1 and E 2 represent -CI and E 3 represents -CI, -OH or -OCH 3 ; or E 1 and E 2 represent -CH 3 and E 3 represents -F or -OCH 3 ; or
  • E 2 and E 3 represent -CI and E 1 represents -CH 3 ; or
  • E 2 represents hydrogen
  • E 1 , E 3 and E 4 represent -F; or
  • E 3 and E 4 represent -CI and E 1 represents -CH 3 ; or
  • E 1 and E 4 represent -CI and E 1 represents -OCH 3 ; or
  • E 1 and E 4 represent -CH 3 and E 3 represents -F, -CH 3 or -OCH 3 ; or
  • E 1 represents -F
  • E 3 represents -CH 3 and E 4 represents -CI
  • E 1 represents -CI
  • E 3 represents -F
  • E 4 represents -CH 3 ;
  • E 1 represents -CI
  • E 3 represents -CH 3 and E 4 represents -F;
  • E 1 and E 4 represent -CH 3 and E 3 represents -F; or
  • E 1 represents -CH 3
  • E 4 represents -CI and E 3 represents -CF 3 or -OCH 3
  • E 1 represents hydrogen
  • E 2 and E 4 represent -CH 3 and E 3 represents -OH; or
  • E 3 represents hydrogen
  • E 1 and E 2 represent -CI and E 4 represents -CH 3 .
  • E 3 and E 4 represent hydrogen
  • E 1 represents -F and E 2 represents -F, -CI, or -CF 3 ; or
  • E 1 represents -CI and E 2 represents -CI, -CH 3 or -CF 3 ; or
  • E 1 and E 3 represent -F;
  • E 1 represents -CI and E 3 represents -F or -CI; or
  • E 1 represents -CH 3 and E 3 represents -CI; or E 2 and E 3 represent hydrogen; and
  • E 1 represents -F and E 4 represents -CI, -CH 3 or -CN; or
  • E 1 represents -CI and E 4 represents -F, -CI, -CH 3 or -CF 3 ; or
  • E 1 represents -CH 3 and E 4 represent, -CI, -CH 3 , -CF 3 , -CN or
  • E 1 represents -CF 3 and E 4 represents -F or -CF 3 ;
  • E 1 represents -CN and E 4 represents -CI; or E 4 represents hydrogen;
  • E 1 , E 2 and E 3 represent -F;
  • E 1 and E 2 represent -CH 3 and E 3 represents -F 3 ; or
  • E 2 and E 3 represent -CI and E 1 represents -CH 3 ; or E 2 represents hydrogen;
  • E 1 , E 3 and E 4 represent -F; or
  • E 3 and E 4 represent -CI and E 1 represents -CH 3 ; or
  • E 1 and E 4 represent -CH 3 and E 3 represents -F or -CH 3 ; or
  • E 1 represents -F
  • E 3 represents -CH 3 and E 4 represents -CI
  • E 1 represents -CI
  • E 3 represents -F
  • E 4 represents -CH 3 ;
  • E 1 represents -CI
  • E 3 represents -CH 3 and E 4 represents -F;
  • E 1 and E 4 represent -CH 3 and E 3 represents -F; or
  • E 1 represents -CH 3 , E 3 represents -CF 3 and E 4 represents -CI; or E 1 represents hydrogen;
  • E 2 and E 4 represent -CH 3 and E 3 represents -OH; or
  • E 3 represents hydrogen
  • E 1 and E 2 represent -CI and E 4 represents -CH 3 .
  • Preferred compounds of formula I include those in which: (a) Z 1 is not present or is selected from -F, -CN, -C(0)R b2 , -C(0)N(R c2 )R d2 , -C(0)OR e2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SCO ⁇ N ⁇ R 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl represented by
  • Z 2 is not present or is selected from-F, -R a2 , -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SCO ⁇ N R ⁇ R" 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl optionally substituted by one or more substituents selected from W 6 , or
  • Z 3 is not present or is selected from -F, -R a2 , -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , - S(0) m R t2 , -SCO ⁇ N R ⁇ R" 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 ; and/or
  • Z 4 is not present or is selected from -F, -C(0)N(R c2 )R d2 , -N(R f2 )R 92 , -N(R h2 )C(0)R i2 , -N(R j2 )C(0)OR k2 , -N(R l2 )C(0)N(R m2 )R n2 , -N(R o2 )S(0) 2 R p2 , -OR q2 , -S(0) m R t2 , -SCO ⁇ N R ⁇ R" 2 , heterocycloalkyl optionally substituted by one or more substituents selected from W 5 , aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 .
  • Particularly preferred compounds of formula I include those in which Z 1 represents -F, -CN, -C(0)NH 2 , -C(0)N(R c2 )R d2 ,
  • Preferred compounds of formula I where Z 1 represents heterocycloalkyi that may be mentioned are those where Z 1 represents dihydropyridinyl, imidazolinyl, morpholinyl, oxanyl, piperazinyl, piperidinyl, pyrrolidinyl and quinuclidinyl, wherein the heterocycloalkyi is optionally substituted by one or more substituents selected from W 5 .
  • each W 7 , W 10 and W 11 independently represents hydrogen, halogen, -R a3 or -CN;
  • one of W 8 and W 9 represents hydrogen, halogen, -R a3 or -CN and the other represents halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 , -N(R j3 )C(0)OR k3 , -N(R l3 )C(0)N(R m3 )R n3 , -N(R o3 )S(0) 2 R p3 , -OR q3x , -OC(0)R r3 , -OS(0) 2 R s3 , -S(0) m R t3 , -SCO ⁇ NCR ⁇ R 3 , heterocycloalkyi optionally substituted by one or more substituents selected from G 1 ,
  • each W 7 , W 10 and W 11 independently represents -F, -CI, -CH 3 , -CF 3 , or more preferably, hydrogen;
  • W 8 and W 9 represents -F, -CI, -CH 3 , -CF 3 , or more preferably, hydrogen, and the other (preferably W 9 ) represents halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 ,
  • W 8 , W 9 , W 10 and W 11 represents hydrogen and W 7 represents -CI or -S(0) 2 CH 3 ;
  • W 7 , W 9 , W 10 and W 11 represents hydrogen and W 8 represents -F, -Br, -CN, -N(H)C(0)CH 3 , -OCH3 or -S(0) 2 CH 3 ; or
  • W 8 and W 9 represents -F or -CI
  • W 8 represents -F and W 9 represents -CH 3 .
  • W 7 , W 8 , W 10 and W 11 are hydrogen and W 9 represents halogen, -R a3 , -CN, -C(0)R b3 , -C(0)N(R c3 )R d3 , -C(0)OR e3 , -N(R f3 )R 93 , -N(R h3 )C(0)R i3 , -N(R j3 )C(0)OR k3 , -N(R l3 )C(0)N(R m3 )R n3 ,
  • W 7 , W 8 , W 10 and W 11 are hydrogen and W 9 represents -F, -CI, -CH 3 , cyclopropyl, -CF 3 , -CN, -NH 2 , -N(CH 3 ) 2 , -N(H)C(0)CH 3 , -N(H)C(0)OC(CH 3 ) 3 , -S0 2 CH 3 , -S0 2 NH 2 , -S(0) 2 N(CH 3 ) 2 , -S(0) 2 -4-morpholinyl, 4-methylpiperazin-1-yl, 4-methylpiperidin-1-ylmethyl and 1 ,2,3-thiadiazol-4-yl.
  • Preferred compounds of formula I where Z 1 represents heteroaryl are those where Z 1 represents benzimidazolyl, benzodioxinyl, benzoxazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, isoquinolinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolopyridinyl, quinolinyl, thiazolyl, thiophenyl and triazolyl, wherein the heteroaryl is optionally substituted by one or more substituents selected from W 6 .
  • Z 1 represents heteroaryl that may be mentioned are those where Z 1 represents benzimidazol-2-yl, 1 ,4-benzo- dioxin-2-yl, benzoxazol-2-yl, furan-2-yl, imidazol-1-yl, imidazol-4-yl, imidazo- [1 ,2-a]pyridin-2-yl, indol-3-yl, indol-5-yl, isoquinolin-4-yl, 1 ,3,4-oxadiazol-2-yl, 1 ,2-oxazol-4-yl, pyrazin-3-yl, pyrazol-1-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5/-/,6/-/,7/-/-pyrrolo[3,4-£>]pyridin-5-yl, thiazol-5-y
  • More particularly preferred compounds of formula I that may be mentioned are those where W 6 represents -F, -CI, -Br, -CH 3 , cyclopropyl, -CF 3 , -CN, -NH 2 , -N(CH 3 ) 2 , -SO2CH3, -SO2NH2 and -SO) 2 N(CH 3 ) 2 .
  • the compound according to the invention is selected from the compounds of Examples 1-454
  • prodrugs of compounds of the invention.
  • prodrug of a compound of the invention we include compounds that form a compound of the invention, in an experimentally-detectable amount, within a predetermined time, following enteral or parenteral administration (e.g. oral or parenteral administration). All prodrugs of the compounds of the invention are included within the scope of the invention.
  • certain compounds of the invention may possess no or minimal pharmacological activity as such, but may be administered parenterally or orally, and thereafter be metabolised in the body to form compounds of the invention that possess pharmacological activity as such.
  • Such compounds (which also includes compounds that may possess some pharmacological activity, but that activity is appreciably lower than that of the "active" compounds of the invention to which they are metabolised), may also be described as "prodrugs".
  • the compounds of the invention are useful because they possess pharmacological activity, and/or are metabolised in the body following oral or parenteral administration to form compounds, which possess pharmacological activity.
  • the compounds of the invention may be useful in the treatment of cancer.
  • the term "treatment” includes treatment per se, prevention and prophylaxis.
  • compounds of the invention may be useful in the the treatment of cancer.
  • the cancer is selected from the group comprising: Soft Tissue
  • sarcoma angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma
  • myxoma rhabdomyoma
  • fibroma lipoma and teratoma
  • Lung bronchogenic carcinoma (squamous cell, undifferentiated small cell
  • adenocarcinoma undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocar
  • fibrosarcoma malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligode
  • schwannoma retinoblastoma, congenital tumors
  • spinal cord neurofibroma meningioma, glioma, sarcoma
  • Gynecological uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli- Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic
  • malignant lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids; neurofibromatosis and Adrenal glands: neuroblastoma.
  • carcinomarous cell includes a cell afflicted by any one of the above identified conditions.
  • the cancer is a solid tumor cancer. In certain embodiments of the present invention, the cancer is selected from pancreatic cancer, ovarian cancer and colorectal cancer.
  • the cancer is selected from colorectal cancer (including Ras mutations), small cell lung cancer, non-small cell lung cancer, and glioma. In certain embodiments of the present invention, the cancer is selected from non- small cell lung cancer, ovarian cancer, metastatic breast cancer, pancreatic cancer, hepatobiliary cancer (including hepatocellular cancer, bile duct cancer and cholangiocarcinoma), and gastric cancer.
  • the cancer is selected from colorectal cancer (including Ras mutations), small cell lung cancer, non-small cell lung cancer, ovarian cancer, hepatobiliary cancer (including hepatocellular cancer, bile duct cancer and cholangiocarcinoma), gastric cancer, testicular cancer, and head and neck squamous cell carcinoma.
  • colorectal cancer including Ras mutations
  • small cell lung cancer non-small cell lung cancer
  • gastric cancer testicular cancer
  • testicular cancer testicular cancer
  • head and neck squamous cell carcinoma head and neck squamous cell carcinoma
  • the cancer is selected from leukemia (including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphoid leukemia), lymphoma (including mantle cell lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), and prostate cancer
  • leukemia including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphoid leukemia
  • lymphoma including mantle cell lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma
  • prostate cancer Compounds of the invention will normally be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, sublingually, intranasally, topically, by any other parenteral route or via inhalation, in a pharmaceutically acceptable dosage form.
  • Compounds of the invention may be administered alone, but are preferably administered by way of known pharmaceutical compositions/formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or
  • Compounds of the invention may be administered in the form of tablets or capsules, e.g., time-release capsules that are taken orally.
  • the compounds of the invention may be in a liquid form and may be taken orally or by injection.
  • the compounds of the invention may also be in the form of suppositories, or, creams, gels, and foams e.g. that can be applied to the skin.
  • they may be in the form of an inhalant that is applied nasally.
  • compositions/formulations may be prepared in accordance with standard and/or accepted pharmaceutical practice.
  • composition/formulation including a compound of the invention, as hereinbefore defined, optionally in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.
  • Such compositions/formulations may be of use in the treatment, prevention and/or prophylaxis of cancer and diseases which benefit by inhibition of MTH1.
  • pharmaceutical formulations that may be mentioned include those in which the active ingredient is present in at least 1 % (or at least 10%, at least 30% or at least 50%) by weight. That is, the ratio of active ingredient to the other components (i.e. the addition of adjuvant, diluent and carrier) of the pharmaceutical composition is at least 1 :99 (or at least 10:90, at least 30:70 or at least 50:50) by weight.
  • the invention further provides a process for the preparation of a pharmaceutical formulation, as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined, or a pharmaceutically acceptable salt thereof with a pharmaceutically-acceptable adjuvant, diluent or carrier.
  • the present invention provides methods for the treatment of cancer comprising administering a therapeutically effective amount of a compound of the invention to a subject (e.g. patient) in need of such treatment.
  • Patients include mammalian (including human) patients.
  • the term "effective amount” refers to an amount of a compound, which confers a therapeutic effect on the treated patient.
  • the effect may be objective (i.e.
  • test or marker measurable by some test or marker
  • subjective i.e. the subject gives an indication of or feels an effect
  • Compounds of the invention may also be combined with other therapeutic agents that are useful in the treatment of cancer.
  • a combination product comprising:
  • each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.
  • Such combination products provide for the administration of a compound of the invention in conjunction with the other therapeutic agent, and may thus be presented either as separate formulations, wherein at least one of those formulations comprises a compound of the invention, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single formulation including a compound of the invention and the other therapeutic agent).
  • a pharmaceutical formulation including a compound of the invention, as hereinbefore defined, another therapeutic agent that is useful in the treatment of cancer, and a pharmaceutically-acceptable adjuvant, diluent or carrier; and (2) a kit of parts comprising components:
  • components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
  • the invention further provides a process for the preparation of a combination product as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined, or a pharmaceutically acceptable salt thereof with the other therapeutic agent that is useful in the treatment of cancer, and at least one pharmaceutically-acceptable adjuvant, diluent or carrier.
  • Compounds of the invention may be administered at varying doses.
  • Oral, pulmonary and topical dosages may range from between about 0.01 mg/kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably about 0.01 to about 10 mg/kg/day, and more preferably about 0.1 to about 5.0 mg/kg/day.
  • the compositions typically contain between about 0.01 mg to about 2000 mg, for example between about 0.1 mg to about 500 mg, or between 1 mg to about 100 mg, of the active ingredient.
  • the most preferred doses will range from about 0.001 to about 10 mg/kg/hour during constant rate infusion.
  • compounds may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • the physician or the skilled person, will be able to determine the actual dosage which will be most suitable for an individual patient, which is likely to vary with the route of administration, the type and severity of the condition that is to be treated, as well as the species, age, weight, sex, renal function, hepatic function and response of the particular patient to be treated.
  • the above- mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the above- stated indications or otherwise.
  • compounds of the invention may have the advantage that they are more efficacious and/or exhibit advantageous properties in vivo.
  • HATU (1-[Bis(dimethylamino)methylene]-1 H-1 ,2,3-triazolo- [4,5-b]pyridinium 3-oxid hexafluorophosphate
  • Step 1 6-bromo-4-chloro-2H-1 ,3-benzodioxole:
  • Step 2 (7-chloro-2H-1 ,3-benzodioxol-5-yl)boronic acid:
  • Step 1 4-Bromo-2,3-dichlorophenol.
  • Step 2 1-Bromo-2,3-dichloro-4-methoxybenzene.
  • Step 3 (2,3-dichloro-4-methoxyphenyl)boronic acid.
  • Step 1 1-Bromo-3-chloro-5-methoxybenzene.
  • Step 2 1-Bromo-2,3-dichloro-5-methoxybenzene.
  • Step 1 ethyl 2-ethoxy-3,4,5,6-tetrahydropyridine-3-carboxylate.
  • Step 2 2-amino-3H,4H,5H,6H,7H,8H-pyrido[2,3-d]pyrimidin-4-one.
  • Step 3 4-chloro-5H,6H,7H,8H-pyrido[2,3-d]pyrimidin-2-amine.
  • a mixture of 2-amino-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-4(3H)-one and acetic anhydride was heated at reflux for 1 h until completion of the reaction as monitored by LCMS.
  • the solvent was removed under reduced pressure and the obtained residue was treated with benzyltnethylammonium chloride (547 mg, 2.4 mmol, 2 eq.) and POCI 3 (671 ⁇ _, 7.2 mmol, 6 eq.) and heated at reflux for 1 h.
  • phenylboronic acid (2.45 g, 20.12 mmol, 1.1 eq.), K 2 C0 3 (5.06 g, 36.6 mmol, 2 eq.) and Pd(PPh 3 ) 4 (700 mg, 0.6 mmol, 0.03 eq.) in 1 ,4-dioxane (15 mL) and water (1 mL) was heated in a sealed tube at 95°C for 12 h. The mixture was run through a plug of silica using EtOAc as eluent, concentrated and purified by column chromatography (1 :4 EtOAc/pentane) to give the desired product as a white solid (2.2 g, 60 %).
  • 6-chloro-4-N-propylpyrimidine-2,4-diamine 6-chloro-4-N-propylpyrimidine-2,4-diamine.
  • a solution of 4,6-dichloropyrimidin-2-amine (820 mg, 5.0 mmol, 1 eq.) in EtOH (40 mL) was treated with propan-1 -amine (5.0 ml).
  • the reaction mixture was stirred at 85 °C for 48h.
  • the mixture was cooled, concentrated by evaporation then flash-chromatographed over silica to afford the product as a colorless solid (705 mg; 76%).
  • 6-chloro-4-N-cyclopropylpyrimidine-2,4-diamine 6-chloro-4-N-cyclopropylpyrimidine-2,4-diamine.
  • cyclopropanamine 80 ⁇ _, 1.1 mmol, 1.1 eq.
  • Hunig ' s base 260 ⁇ _, 1.5 mmol, 1.5 eq.
  • the reaction mixture was stirred overnight at 95 °C.
  • the solvent was removed in vacuo.
  • the crude product was diluted in EtOAc and washed with H 2 0, brine, dried over MgS0 4 and
  • 6-chloro-4-N-(2-phenylethyl)pyrimidine-2,4-diamine 6-chloro-4-N-(2-phenylethyl)pyrimidine-2,4-diamine.
  • 4-6-dichloropyrimidin-2-amine 66 mg, 0.40 mmol, 1 eq.
  • 2-phenylethanamine 75 ⁇ _, 0.60 mmol, 1.1 eq.
  • Hunig ' s base 100 ⁇ g, 0.60 mmol, 1.1 eq.
  • the reaction mixture was stirred at 95 °C for 3 h.
  • the solvent was removed in vacuo.
  • the crude product was diluted in EtOAc and washed with H 2 0, brine, dried over MgS0 4 and concentrated to afford the desired product as a yellow solid (88 mg, 88 %).
  • Step 1 To a suspension of 4,6-dichloropyrimidin-2-amine (500 mg, 3.05 mmol) and Hunig's base (0.80 ml_) in 2-propanol (3.0 ml_) was added tert-butyl N-(2- aminoethyl)carbamate (586 mg, 3.66 mmol) and the mixture was stirred at 150 °C for 15 min. The crude mixture was poured into NaHC03 (aq) and extracted three times with DCM. The combined organic layers were dried and concentrated.
  • Step 2 tert-Butyl N-[2-[(2-amino-6-chloro-pyrimidin-4-yl)amino]ethyl]carbamate (850 mg, 2.95 mmol), (2,3-dimethylphenyl)boronic acid (532 mg, 3,55 mmol), palladium tetrakis(triphenylphosphine)palladium (0) (34 mg, 0.030 mmol), and K 2 C0 3 (1020 mg, 7.39 mmol) were suspended in 1 ,4-dioxane (10 ml) and H 2 0 (2.0 ml). The vial was flushed with nitrogen and the resulting mixture was stirred at 90 °C for 16 h.
  • Step 3 tert-Butyl N-[2-[[2-amino-6-(2,3-dimethylphenyl)pyrimidin-4- yl]amino]ethyl]carbamate (770 mg, 2.15 mmol) was dissolved in TFA (6 ml_) and the resulting mixture was stirred for 1 h at rt, after which the TFA was distilled off. Purification by column chromatography (5 ⁇ 30% MeOH [containing 1 v/v% NH4OH] in DCM) afforded 4-N-(2-aminoethyl)-6-(2,3-dimethylphenyl)pyrimidine- 2,4-diamine (500 mg, 1.94 mmol). LCMS [M+H] + 258.
  • Step 1 A vial was charged with 4,6-dichloropyrimidin-2-amine (500 mg, 3.0 mmol) and tert-butyl N-(2-aminopropyl)carbamate (640 mg, 3.7 mmol). Then 2- propanol (3.0 ml) and Hunig's base (0.80 ml) were added and the resulting mixture was heated at 150 °C using microwave irradiation for 15 min.
  • Step 2 tert-Butyl N-[3-[(2-amino-6-chloro-pyrimidin-4-yl)amino]propyl]carbamate (790 mg, 2.6 mmol), (2,3-dimethylphenyl)boronic acid (470 mg, 3.1 mmol), palladium tetrakis(triphenylphosphine)palladium (0) (60 mg, 0.050 mmol), and K2CO 3 (720 mg 5.2 mmol) were suspended in 1 ,4-dioxane (6.0 ml) and H 2 0 (1.5 ml). The resulting mixture was heated at 90 °C for 16 h and then poured into H 2 0 and extracted three times with DCM.
  • 2,3-dimethylphenyl)boronic acid 470 mg, 3.1 mmol
  • palladium tetrakis(triphenylphosphine)palladium (0) 60 mg, 0.050 mmol
  • Tetrakis(triphenylphosphine)palladium (0) (5 mol%) was added to a stirred mixture of 6-chloro-4-N-methylpyrimidine-2,4-diamine (1.00 mmol), (3- aminophenyl)boronic acid (1.3 eq.), sodium carbonate (3.2 eq.), 1 ,4-dioxane (4 ml_) and water (1 mL) in a tube. The tube was sealed and the reaction was heated at 90°C for 5 h and then concentrated. The crude material was taken up in ethyl acetate and washed with water. The organic phase was dried over magnesium sulfate, concentrated and purified by flash chromatography (0 ⁇ 15 % MeOH in DCM) to give the title compound. LCMS [M+H] + 216.
  • Tetrakis(triphenylphosphine)palladium (0) (5 mol%) was added to a stirred mixture of 6-chloro-4-N-methylpyrimidine-2,4-diamine (3.00 mmol), (3-amino-2- methylphenyl)boronic acid (1.3 eq.), sodium carbonate (3.2 eq.), 1 ,4-dioxane (4 mL) and water (1 mL). The tube was sealed and the reaction was heated at 90°C for 5 h. The mixture was concentrated and purified by column chromatography (13% MeOH in DCM) to give the title compound.
  • Tetrakis(triphenylphosphine)palladium (0) (5 mol%) was added to a stirred mixture of 6-chloro-4-N-methylpyrimidine-2,4-diamine (3.0 mmol), (5-amino-2- methylphenyl)boronic acid (1.3 eq.), sodium carbonate (3.2 eq.), 1 ,4-dioxane (4 ml_) and water (1 ml_) in a tube. The tube was sealed and the reaction was heated at 90°C for 5 h. The mixture was concentrated and purified by column chromatography (13 % MeOH in DCM) to give the title compound. LCMS [M+H] + 230.
  • Tetrakis(triphenylphosphine)palladium (0) (5 mol%) was added to a stirred mixture of 6-chloro-4-N-methylpyrimidine-2,4-diamine (1.0 mmol), 4-(tetramethyl- 1 ,3,2-dioxaborolan-2-yl)aniline (1.3 eq.), sodium carbonate (3.2 eq.), 1 ,4-dioxane (4 ml_) and water (1 ml_) in a tube. The tube was sealed and the reaction was heated at 90°C for 5 h and then concentrated. The crude material was taken up in ethyl acetate and washed with water.
  • the utility of the compounds of the present invention can be illustrated, for example, by their activity in vitro in the cancer cell clonogenic and/or viability assay described below.
  • the link between activity in tumor cell clonogenic assay and anti-tumor activity in the clinical setting has been well established in the art (e.g. see ref Silverstini et al Stem Cells 1993, 11 (6), 258-35).
  • Example 1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/SE2013/051387 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer Ceased WO2014084778A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
US14/647,400 US9604937B2 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
JP2015544036A JP6322205B2 (ja) 2012-11-27 2013-11-26 がん治療用のピリミジン−２，４−ジアミン誘導体
SG11201503783VA SG11201503783VA (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
PL13859400T PL2925744T3 (pl) 2012-11-27 2013-11-26 Pochodne pirymidyno-2,4-diaminy do leczenia nowotworu
KR1020157015196A KR102194646B1 (ko) 2012-11-27 2013-11-26 암 치료를 위한 피리미딘-2,4-다이아민 유도체
EP13859400.7A EP2925744B1 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
NZ70909413A NZ709094A (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
AU2013353542A AU2013353542B2 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
RU2015125458A RU2672916C2 (ru) 2012-11-27 2013-11-26 Производные пиримидин-2,4-диамина для лечения рака
BR112015011497-0A BR112015011497B1 (pt) 2012-11-27 2013-11-26 Composto, e, formulação farmacêutica
CA2888338A CA2888338C (en) 2012-11-27 2013-11-26 Mth1 inhibitors for treatment of cancer
MYPI2015001271A MY182386A (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
DK13859400.7T DK2925744T3 (da) 2012-11-27 2013-11-26 Pyrimidin-2,4-diamin-derivater til behandling af kræft
MX2015006039A MX373786B (es) 2012-11-27 2013-11-26 Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
ES13859400T ES2860937T3 (es) 2012-11-27 2013-11-26 Derivados de pirimidina-2,4-diamina para el tratamiento del cáncer
CN201380061606.XA CN105143206B (zh) 2012-11-27 2013-11-26 用于治疗癌症的嘧啶-2,4-二胺衍生物
HK16103963.9A HK1216025B (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
PH12015501058A PH12015501058A1 (en) 2012-11-27 2015-05-13 Pyrimidine-2,4-diamine derivatives for treatment of cancer
ZA2015/03470A ZA201503470B (en) 2012-11-27 2015-05-18 Pyrimidine-2,4-diamine derivatives for treatment of cancer
IL238942A IL238942B (en) 2012-11-27 2015-05-21 History of pyrimidine-4,2-diamine for cancer treatment
SA515360493A SA515360493B1 (ar) 2012-11-27 2015-05-27 مشتقات بيريميدين-2، 4-داي أمين لعلاج السرطان
US15/447,818 US9944640B2 (en) 2012-11-27 2017-03-02 Pyrimidine-2,4-diamine derivatives for treatment of cancer
US15/899,061 US10174029B2 (en) 2012-11-27 2018-02-19 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261797022P 2012-11-27 2012-11-27
SE1251332-1 2012-11-27
SE1251332 2012-11-27
US61/797,022 2012-11-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/647,400 A-371-Of-International US9604937B2 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer
US15/447,818 Continuation US9944640B2 (en) 2012-11-27 2017-03-02 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Publications (1)

Publication Number Publication Date
WO2014084778A1 true WO2014084778A1 (en) 2014-06-05

Family

ID=50828272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2013/051387 Ceased WO2014084778A1 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Country Status (19)

Country Link
US (3) US9604937B2 (enExample)
EP (1) EP2925744B1 (enExample)
JP (1) JP6322205B2 (enExample)
KR (1) KR102194646B1 (enExample)
CN (1) CN105143206B (enExample)
AU (1) AU2013353542B2 (enExample)
BR (1) BR112015011497B1 (enExample)
CA (1) CA2888338C (enExample)
CL (1) CL2015001437A1 (enExample)
IL (1) IL238942B (enExample)
MX (1) MX373786B (enExample)
MY (1) MY182386A (enExample)
PE (1) PE20151412A1 (enExample)
PH (1) PH12015501058A1 (enExample)
PL (1) PL2925744T3 (enExample)
RU (1) RU2672916C2 (enExample)
SG (1) SG11201503783VA (enExample)
WO (1) WO2014084778A1 (enExample)
ZA (1) ZA201503470B (enExample)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292213A (zh) * 2014-09-08 2015-01-21 湖南华腾制药有限公司 一种嘧啶衍生物的制备方法
WO2015172747A1 (en) * 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
WO2015187088A1 (en) * 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
JP2016124812A (ja) * 2014-12-26 2016-07-11 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
WO2016128140A1 (en) 2015-02-13 2016-08-18 Merck Patent Gmbh Pyrimidine derivatives for use in the treatment of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016145383A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Mth1 inhibitors for treating disease
EP3151833A4 (en) * 2014-06-04 2018-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
US10195196B2 (en) 2012-08-13 2019-02-05 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
WO2019166639A1 (en) 2018-03-01 2019-09-06 Thomas Helledays Stiftelse För Medicinsk Forskning Substituted benzodiazoles and use thereof in therapy
US10961254B2 (en) 2014-06-13 2021-03-30 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
WO2021063852A1 (en) * 2019-09-30 2021-04-08 F. Hoffmann-La Roche Ag Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
US11241431B2 (en) 2015-11-20 2022-02-08 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives as PGE2 receptor modulators
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
WO2022260441A1 (en) * 2021-06-09 2022-12-15 Avelos Therapeutics Inc. Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents
US11712438B2 (en) 2017-05-18 2023-08-01 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
US12435054B2 (en) 2020-07-24 2025-10-07 Genentech, Inc. Therapeutic compounds and methods of use

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015011497B1 (pt) * 2012-11-27 2023-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Composto, e, formulação farmacêutica
CN106928192B (zh) * 2015-12-29 2020-11-13 中国科学院广州生物医药与健康研究院 一种嘧啶类化合物及其制备方法和应用
CN105732516A (zh) * 2016-03-09 2016-07-06 哈尔滨医科大学 一种合成mth1蛋白抑制剂th287的方法
WO2017190050A1 (en) * 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
KR101876514B1 (ko) * 2016-11-08 2018-07-10 한국화학연구원 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
WO2019134082A1 (en) * 2018-01-04 2019-07-11 Wuxi Advant Biotechnology Co., Ltd. Novel pyrimidine derivatives as mth1 inhibitors
CN113924085A (zh) * 2019-04-12 2022-01-11 加利福尼亚大学董事会 用于增加肌肉量和氧化代谢的组合物和方法
WO2021097110A1 (en) * 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
CN110872291B (zh) * 2019-11-26 2021-06-25 五邑大学 一种四氢吡啶并嘧啶类化合物及其制备方法和应用
CN111557940A (zh) * 2020-05-28 2020-08-21 青岛大学附属医院 Mth1抑制剂th588在制备治疗多发性骨髓瘤的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB681712A (en) * 1949-09-14 1952-10-29 Burroughs Wellcome Co Improvements in or relating to therapeutically useful pyrimidine compounds
US20080194577A1 (en) * 2007-02-14 2008-08-14 Hui Cai 2-Aminopyrimidine modulators of the histamine H4 receptor
WO2011056916A1 (en) * 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
WO2011100285A1 (en) * 2010-02-10 2011-08-18 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
US20110275611A1 (en) * 2008-11-20 2011-11-10 Jeffrey Michael Axten Chemical compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2691655A (en) * 1952-05-24 1954-10-12 Burroughs Wellcome Co 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same
EP0210228A1 (en) 1985-02-05 1987-02-04 The Upjohn Company 4-substituted-6-aryl pyrimidine compounds
US6169086B1 (en) 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
US6573377B1 (en) * 1998-07-24 2003-06-03 Daiichi Pharmaceuticals Co., Ltd. Pyrazole derivatives and salts thereof
AU2002310187A1 (en) * 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
EP1418911B1 (en) 2001-08-13 2006-05-10 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
MXPA06010900A (es) 2004-03-26 2007-02-21 Methylgene Inc Inhibidores de histona desacetilasa.
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
CA2714743C (en) * 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US8268846B2 (en) * 2008-07-11 2012-09-18 Abbott Laboratories Amino heterocyclic linked pyrimidine derivatives
ES2650744T3 (es) 2010-12-14 2018-01-22 Electrophoretics Limited Inhibidores de la caseína quinasa 1 delta (CK1delta)
GB201215502D0 (en) 2012-08-31 2012-10-17 Chalkiadakis Spyridon Medical use
BR112015011497B1 (pt) * 2012-11-27 2023-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Composto, e, formulação farmacêutica

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB681712A (en) * 1949-09-14 1952-10-29 Burroughs Wellcome Co Improvements in or relating to therapeutically useful pyrimidine compounds
US20080194577A1 (en) * 2007-02-14 2008-08-14 Hui Cai 2-Aminopyrimidine modulators of the histamine H4 receptor
US20110275611A1 (en) * 2008-11-20 2011-11-10 Jeffrey Michael Axten Chemical compounds
WO2011056916A1 (en) * 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
WO2011100285A1 (en) * 2010-02-10 2011-08-18 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] XP055260721, retrieved from STN Database accession no. 634582-11-9 *
DATABASE REGISTRY 5 January 2004 (2004-01-05), retrieved from STN Database accession no. 634195-07-6 *
DATABASE REGISTRY 6 January 2004 (2004-01-06), retrieved from STN Database accession no. 634195-10-1 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195196B2 (en) 2012-08-13 2019-02-05 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US11229648B2 (en) 2012-08-13 2022-01-25 Novartis Ag 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions
US10758533B2 (en) 2012-08-13 2020-09-01 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
WO2015172747A1 (en) * 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
WO2015187088A1 (en) * 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
EP3151833A4 (en) * 2014-06-04 2018-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
EP3154547B1 (en) * 2014-06-13 2023-06-07 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
US10961254B2 (en) 2014-06-13 2021-03-30 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
CN104292213A (zh) * 2014-09-08 2015-01-21 湖南华腾制药有限公司 一种嘧啶衍生物的制备方法
JP2016124812A (ja) * 2014-12-26 2016-07-11 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
WO2016128140A1 (en) 2015-02-13 2016-08-18 Merck Patent Gmbh Pyrimidine derivatives for use in the treatment of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016145383A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Mth1 inhibitors for treating disease
US12011444B2 (en) 2015-11-20 2024-06-18 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives as PGE2 receptor modulators
US11241431B2 (en) 2015-11-20 2022-02-08 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives as PGE2 receptor modulators
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
US11712438B2 (en) 2017-05-18 2023-08-01 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
WO2019166639A1 (en) 2018-03-01 2019-09-06 Thomas Helledays Stiftelse För Medicinsk Forskning Substituted benzodiazoles and use thereof in therapy
WO2021063852A1 (en) * 2019-09-30 2021-04-08 F. Hoffmann-La Roche Ag Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
US12435054B2 (en) 2020-07-24 2025-10-07 Genentech, Inc. Therapeutic compounds and methods of use
WO2022260441A1 (en) * 2021-06-09 2022-12-15 Avelos Therapeutics Inc. Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Also Published As

Publication number Publication date
KR20150087271A (ko) 2015-07-29
CN105143206B (zh) 2019-01-15
PH12015501058B1 (en) 2015-08-10
KR102194646B1 (ko) 2020-12-23
BR112015011497B1 (pt) 2023-01-10
CL2015001437A1 (es) 2015-12-28
MY182386A (en) 2021-01-22
AU2013353542A1 (en) 2015-07-02
IL238942B (en) 2018-02-28
ZA201503470B (en) 2017-11-29
EP2925744B1 (en) 2020-12-30
AU2013353542B2 (en) 2018-04-05
PE20151412A1 (es) 2015-10-10
HK1216025A1 (en) 2016-10-07
PH12015501058A1 (en) 2015-08-10
MX2015006039A (es) 2015-10-20
US9604937B2 (en) 2017-03-28
US20170217961A1 (en) 2017-08-03
CA2888338C (en) 2021-07-20
US20160002175A1 (en) 2016-01-07
CN105143206A (zh) 2015-12-09
EP2925744A4 (en) 2016-08-24
US20180170929A1 (en) 2018-06-21
PL2925744T3 (pl) 2021-06-14
SG11201503783VA (en) 2015-06-29
RU2672916C2 (ru) 2018-11-21
JP2016504289A (ja) 2016-02-12
RU2015125458A (ru) 2017-01-11
BR112015011497A2 (pt) 2017-07-11
US10174029B2 (en) 2019-01-08
IL238942A0 (en) 2015-07-30
EP2925744A1 (en) 2015-10-07
CA2888338A1 (en) 2014-06-05
MX373786B (es) 2020-03-23
JP6322205B2 (ja) 2018-05-09
US9944640B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
US10174029B2 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
US10632125B2 (en) MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
KR101940831B1 (ko) (알파-치환된 아르알킬아미노 및 헤테로아릴알킬아미노)피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸, 이들을 함유하는 약학 조성물, 및 증식성 질병의 치료에 사용하기 위한 이들 화합물
US10179790B2 (en) MTH1 inhibitors for treatment of cancer
TW202327602A (zh) 泛素特異性蛋白酶1 (usp1)之小分子抑制劑及其用途
CZ2002534A3 (cs) Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
EP3083631B1 (en) Wnt pathway modulators
KR20120034607A (ko) 이미다조〔2,1-ｂ〕〔1,3,4〕티아디아졸 유도체
CN107074812A (zh) 新型取代的嘧啶化合物
HK1216025B (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
ES2860937T3 (es) Derivados de pirimidina-2,4-diamina para el tratamiento del cáncer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380061606.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13859400

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: DZP2015000171

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2888338

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12015501058

Country of ref document: PH

Ref document number: MX/A/2015/006039

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 000650-2015

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 238942

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2015544036

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14647400

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015011497

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157015196

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201503587

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 2013859400

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15142772

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2015125458

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201505666

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2013353542

Country of ref document: AU

Date of ref document: 20131126

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015011497

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150519